FBXO22 and lung carcinoma: The findings indicated that FBXO22 was remarkably overexpressed in lung cancer and that high expression of FBXO22 was correlated with short overall survival of patients, suggesting that FBXO22 is a biomarker of poor prognosis in lung cancer.